IREDA Stock Soars Following Strong Q3 Performance Update
Shares of the Indian Renewable Energy Development Agency Ltd. surged over 5% on the back of a robust Q3 update, with the state-owned company reporting growth across key financial metrics.
For the December quarter, IREDA registered a 41% year-on-year growth in loan disbursements, reaching a total of Rs 17,236 crore, up from Rs 12,220 crore in the same period last year.
The company also posted a 129% YoY increase in loan sanctions, amounting to Rs 31,087 crore in Q3, compared to Rs 13,558 crore in the corresponding period of 2023.
As a result of this surge in activity, IREDA's outstanding loan book reached Rs 69,000 crore as of December 31, 2024, marking a 36% rise from the Rs 50,580 crore recorded a year ago.
The positive update has led to investor optimism, propelling IREDA's stock price higher, and further solidifying its reputation as a key player in India's renewable energy financing landscape.
The scrip rose as much as 5.76% to Rs 227 apiece. It pared gains to trade 3.41% higher at Rs 222.60 apiece, as of 11:32 a.m. This compares to a 0.41% advance in the NSE Nifty 50 Index.
It has risen 112.71% in the last 12 months. Total traded volume so far in the day stood at 3.8 times its 30-day average. The relative strength index was at 75.24
Out of two analysts tracking the company, one maintains a 'buy' rating, and the other suggests 'sell,' according to Bloomberg data. The average 12-month consensus price target implies an upside of 25.8%
(With inputs from PTI)
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
